SCHEMBL2920433

SCHEMBL2920433

CNC(=O)C1CN(C)CCN1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 1/20 0.40
▸ KCNH2 Q12809 1/20 0.40
▸ GRIN2D O15399 2/20 0.36
▸ GRIN3B O60391 2/20 0.36
▸ THRB P10828 2/20 0.36
▸ GRIN1 Q05586 2/20 0.36
▸ GRIN2A Q12879 2/20 0.36
▸ GRIN2B Q13224 2/20 0.36
▸ GRIN2C Q14957 2/20 0.36
▸ GRIN3A Q8TCU5 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ MC4R P32245 10/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MC5R P33032 6/20 0.32
▸ MC3R P41968 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15072877 1.00 CCR2 (0.40) CCR2KCNH2GRIN2DGRIN3BTHRB
SCHEMBL2912163 0.89 DPP7 (0.35) CCR2KCNH2GRIN2DGRIN3BTHRB
SCHEMBL2914841 0.84 PRCP (0.36) CCR2KCNH2GRIN2DGRIN3BTHRB
SCHEMBL27322587 0.80 CCR2 (0.41) CCR2KCNH2GRIN2DGRIN3BTHRB
SCHEMBL19447676 0.80 GRIN2D (0.32) GRIN2DGRIN3BTHRBGRIN1GRIN2A
SCHEMBL19447591 0.80 GRIN2D (0.32) GRIN2DGRIN3BTHRBGRIN1GRIN2A
SCHEMBL15432264 0.79 SCN9A (0.37) GRIN2DGRIN3BTHRBGRIN1GRIN2A
SCHEMBL13732366 0.79 SCN9A (0.37) GRIN2DGRIN3BTHRBGRIN1GRIN2A
SCHEMBL12995468 0.79 MAPT (0.50) CCR2KCNH2GRIN2DGRIN3BTHRB
SCHEMBL11927512 0.79 CCR2 (0.40) CCR2KCNH2GRIN2DGRIN3BTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023016521-A1 SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 上海赛默罗生物科技有限公司 2023-02-16 — — WO disclosed
US-20160229836-A1 MULTIVALENT RAS BINDING COMPOUNDS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2016-08-11 — — US disclosed
WO-2015184349-A2 MULTIVALENT RAS BINDING COMPOUNDS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2015-12-03 — — WO disclosed
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 — — EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 — — US disclosed
US-20080125409-A1 1,5-Diheterocycle-1H-Triazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-05-29 — — US disclosed
US-20080064682-A1 Pyrazole Derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2008-03-13 — — US disclosed
US-20070254881-A1 Pyrazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-11-01 — — US disclosed
EP-1803719-A1 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-07-04 — — EP disclosed
EP-1785418-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-05-16 — — EP disclosed
EP-1762568-A1 PYRAZOLE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-14 — — EP disclosed
US-20060189591-A1 Five-membered heterocyclic derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-24 — — US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 — — US disclosed
EP-1621537-A1 FIVE-MEMBERED HETEROCYCLIC DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-02-01 — — EP disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125409-A1 1,5-Diheterocycle-1H-Triazole Derivative PTGS1, PTGER1, TBXA2R CCR2 545/4885KCNH2 2346/4885GRIN2D 1369/4885
US-20070254881-A1 Pyrazole Derivative PTGER1, PTGS1, PTGER2 CCR2 2523/4885KCNH2 2311/4885GRIN2D 1644/4885
US-20160229836-A1 MULTIVALENT RAS BINDING COMPOUNDS KRAS, HRAS, G3BP1 CCR2 2082/4885KCNH2 4646/4885GRIN2D 4483/4885
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 CCR2 1765/4885KCNH2 2509/4885GRIN2D 1632/4885
US-20080064682-A1 Pyrazole Derivatives NAT1, AR, CBR3 CCR2 2462/4885KCNH2 813/4885GRIN2D 1070/4885
US-20060189591-A1 Five-membered heterocyclic derivative PTGS1, PTGIS, PTGS2 CCR2 1635/4885KCNH2 2295/4885GRIN2D 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback